Shares of Agenus Inc. (NASDAQ:AGEN – Get Rating) crossed above its 200-day moving average during trading on Tuesday . The stock has a 200-day moving average of $2.31 and traded as high as $2.36. Agenus shares last traded at $2.29, with a volume of 1,931,379 shares traded.
Analyst Upgrades and Downgrades
Separately, TheStreet downgraded shares of Agenus from a “c-” rating to a “d” rating in a research report on Friday, May 27th.
Agenus Trading Down 0.9 %
The company has a market capitalization of $634.29 million, a P/E ratio of 22.30 and a beta of 1.17. The business’s 50-day simple moving average is $2.68 and its 200 day simple moving average is $2.31.
Institutional Trading of Agenus
A number of hedge funds and other institutional investors have recently made changes to their positions in the business. Acadian Asset Management LLC purchased a new position in shares of Agenus in the fourth quarter worth approximately $32,000. U.S. Capital Wealth Advisors LLC purchased a new position in shares of Agenus in the first quarter worth approximately $25,000. Qube Research & Technologies Ltd purchased a new position in shares of Agenus in the fourth quarter worth approximately $40,000. Bank of Nova Scotia purchased a new position in shares of Agenus in the first quarter worth approximately $31,000. Finally, Coastal Bridge Advisors LLC purchased a new position in Agenus during the fourth quarter valued at approximately $42,000. 51.89% of the stock is currently owned by institutional investors.
Agenus Company Profile
Agenus Inc, a clinical-stage immuno-oncology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies.
- Get a free copy of the StockNews.com research report on Agenus (AGEN)
- What Steelcase’s Earnings Say About the Return to the Office?
- The Institutions Hold On To Darden Restaurants International
- Is The Golden Age Of Homebuilding Already Over?
- These 3 Big Dividend Payers Also Boast Strong Price Growth
- Natural Gas Prices Continue To Rally, These Stocks Should Benefit
Receive News & Ratings for Agenus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agenus and related companies with MarketBeat.com's FREE daily email newsletter.